Navigation Links
Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
Date:10/28/2008

Data to be presented at annual ICAAC/IDSA meeting in Washington, D.C.

WASHINGTON, Oct. 28 /PRNewswire/ -- Scientists at NanoBio Corporation have demonstrated for the first time in humans that a novel topical treatment for cold sores (herpes labialis), NB-001, speeds healing of lesions as effectively as the leading oral systemic drugs but without safety or toxicity concerns.

The new data provide the first proof of principle that a topical agent can attain equivalent efficacy rates to oral systemic drugs, according to the NanoBio scientists. Topical treatments are widely considered inferior to oral systemic treatments because they fail to penetrate to the site of infection with adequate drug levels required to subdue infections.

In the study of 482 patients, NB-001 healed lesions 1.3 days faster than placebo as measured by investigators (P=0.006). Results of the randomized, double-blind, placebo-controlled, phase 2b trial are being presented at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual Infectious Diseases Society of America (IDSA) meeting in Washington, D.C.

NB-001 was well tolerated, without safety concerns or adverse events, and was not systemically absorbed. "NB-001 challenges the conventional wisdom that topical therapies are less effective, because NB-001 directly accesses the site of infection in the dermis and epidermis instead of remaining on top of the skin," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "NB-001 employs a physical mode of action to disrupt the outer membranes of pathogens and prompt viral lysis, essentially killing on contact."

The study also suggests that the physical mode of action of NB-001 significantly reduces the likelihood that pathogens will develop resistance to the biocidal effect of the topical lotion.

"These characteristics make NB-001 an ideal candidate for first-line treatment with the potential for widespread use across a broad range of patients," said Mary Flack, M.D., vice president of clinical research at NanoBio and author of the oral presentation.

NanoBio scientists credit the topical lotion's safety and robust anti-infective activity to NB-001's novel technology platform. The lotion is composed of an oil-in-water emulsion and a commonly used antimicrobial surfactant that are mixed at high speeds to nanosize the particles and infuse them with high levels of potential energy. The resulting nanodroplets easily penetrate hair follicles and skin pores to reach the site of infection without damaging skin or mucous membranes. Upon contact with the pathogen, the highly charged particles release their energy to the pathogen's outer membranes, disrupting the viral particle.

"The ability of NB-001 to penetrate skin pores and hair follicles is essential to its activity in the dermis and epidermis, where it surrounds and fuses with herpes simplex virus and disrupts the outer envelope of the pathogen," Flack said. "NB-001 does not compromise tissue integrity, so it is not absorbed into the bloodstream."

Because the herpes simplex virus causes both cold sores and genital herpes, there is a strong potential that NB-001 will also be effective in treating genital lesions, she added.

NanoBio is currently testing its pipeline of topical products against a wide range of skin infections including onychomycosis (nail fungus), tinea capititis (ringworm) and acne.

About NanoBio

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne and a broad platform of mucosal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
2. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
3. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
6. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
7. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
8. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
9. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
10. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... /PRNewswire/ - Demers Ambulances announces its first delivery in the state ... County Emergency Medical Services (EMS) consisting of four ... van. Quality Emergency Vehicles in Lecanto, FL ... This is the latest in Demers, ongoing expansion of sales.  ... Demers. --> Benoit LaFortune , Executive Vice President ...
(Date:2/12/2016)... Feb. 12, 2016   HeartWare International, Inc . ... and webcast to discuss its financial results for the ... Thursday, February 25, 2016 at 8:00 a.m. ET.  The ... the conference call and webcast.  On the conference call ... highlights from the fourth quarter and business outlook.   ...
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... With FCPX Overlay Embers from Pixel Film Studios users can now apply ... user can select from up to 40 effect overlays. With FCPX Overlay Embers users ... value, contrast, glow, and more all within a click of a mouse. , ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Tech Outlook’s top Clinical Data Management Solution Providers list for its expertise in ... functional and domain expertise to serve the technology needs of global clients. DDi ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan ... The purpose of these scholarships is to encourage applicants to pursue a degree in ... within these two parishes. , “We have available jobs in St. Landry and ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn ... 2015 will show what to expect when they come knocking this year. But that takes ...
Breaking Medicine News(10 mins):